DNER and leukemia: To evaluate I-BET resistance in leukemia, we used the pan-BET inhibitor GSK1210151A (I-BET151) [15], in two cell line models: the CML (chronic myeloid leukemia) I-BET-resistant K562 and the AML (acute myeloid leukemia) I-BET-sensitive MV4;11.